BIOMARKER:

KRAS G12C

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Colorectal Cancer

Rectal Cancer

Colon Cancer

Solid Tumor

Pancreatic Cancer

Lung Cancer

Pancreatic Ductal Adenocarcinoma

Gastrointestinal Cancer

Lung Non-Squamous Non-Small Cell Cancer

Lung Adenocarcinoma

Pancreatic Adenocarcinoma

Endometrial Cancer

Ampulla of Vater Carcinoma

Ovarian Cancer

Melanoma

Hepatocellular Cancer

Biliary Tract Cancer

Cholangiocarcinoma

Small Intestinal Carcinoma

Bladder Cancer

Gastric Cancer

Multiple Myeloma

Lung Non-Small Cell Squamous Cancer

panitumumab + sotorasib

KRAS G12C|Rectal Cancer|panitumumab + sotorasib

KRAS G12C|Colon Cancer|panitumumab + sotorasib

KRAS G12C|Colorectal Cancer|panitumumab + sotorasib

panitumumab + adagrasib

KRAS G12C|Rectal Cancer|panitumumab + adagrasib

KRAS G12C|Colon Cancer|panitumumab + adagrasib

cetuximab + sotorasib

KRAS G12C|Rectal Cancer|cetuximab + sotorasib

KRAS G12C|Colon Cancer|cetuximab + sotorasib

adagrasib

KRAS G12C|Non Small Cell Lung Cancer|adagrasib

KRAS G12C|Colorectal Cancer|adagrasib

KRAS G12C|Solid Tumor|adagrasib

KRAS G12C|Pancreatic Cancer|adagrasib

KRAS G12C|Lung Cancer|adagrasib

KRAS G12C|Gastrointestinal Cancer|adagrasib

KRAS G12C|Pancreatic Adenocarcinoma|adagrasib

KRAS G12C|Endometrial Cancer|adagrasib

KRAS G12C|Pancreatic Ductal Adenocarcinoma|adagrasib

KRAS G12C|Ampulla of Vater Carcinoma|adagrasib

KRAS G12C|Lung Adenocarcinoma|adagrasib

KRAS G12C|Ovarian Cancer|adagrasib

KRAS G12C|Biliary Tract Cancer|adagrasib

KRAS G12C|Cholangiocarcinoma|adagrasib

cetuximab + adagrasib

KRAS G12C|Rectal Cancer|cetuximab + adagrasib

KRAS G12C|Colon Cancer|cetuximab + adagrasib

KRAS G12C|Colorectal Cancer|cetuximab + adagrasib

sotorasib

KRAS G12C|Non Small Cell Lung Cancer|sotorasib

KRAS G12C|Colorectal Cancer|sotorasib

KRAS G12C|Pancreatic Cancer|sotorasib

KRAS G12C|Lung Non-Squamous Non-Small Cell Cancer|sotorasib

KRAS G12C|Gastrointestinal Cancer|sotorasib

KRAS G12C|Pancreatic Adenocarcinoma|sotorasib

KRAS G12C|Endometrial Cancer|sotorasib

KRAS G12C|Ampulla of Vater Carcinoma|sotorasib

KRAS G12C|Lung Adenocarcinoma|sotorasib

KRAS G12C|Melanoma|sotorasib

MEK inhibitor + sotorasib

KRAS G12C|Colorectal Cancer|MEK inhibitor + sotorasib

D-1553

KRAS G12C|Non Small Cell Lung Cancer|D-1553

KRAS G12C|Colorectal Cancer|D-1553

KRAS G12C|Solid Tumor|D-1553

KRAS G12C|Pancreatic Cancer|D-1553

KRAS G12C|Lung Cancer|D-1553

GFH925

KRAS G12C|Non Small Cell Lung Cancer|GFH925

KRAS G12C|Colorectal Cancer|GFH925

KRAS G12C|Solid Tumor|GFH925

KRAS G12C|Pancreatic Cancer|GFH925

abemaciclib

KRAS G12C|Non Small Cell Lung Cancer|abemaciclib

JAB-21822

KRAS G12C|Non Small Cell Lung Cancer|JAB-21822

KRAS G12C|Solid Tumor|JAB-21822

KRAS G12C|Pancreatic Cancer|JAB-21822

RG6330

KRAS G12C|Non Small Cell Lung Cancer|RG6330

KRAS G12C|Colorectal Cancer|RG6330

KRAS G12C|Solid Tumor|RG6330

sotorasib + BMS-986466

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + BMS-986466

Immunotherapy

KRAS G12C|Non Small Cell Lung Cancer|Immunotherapy

KRAS G12C|Lung Non-Squamous Non-Small Cell Cancer|Immunotherapy

BI 1823911

KRAS G12C|Lung Cancer|BI 1823911

KRAS G12C|Small Intestinal Carcinoma|BI 1823911

KRAS G12C inhibitor

KRAS G12C|Lung Cancer|KRAS G12C inhibitor

PTPN11 inhibitor + ERK inhibitor

KRAS G12C|Pancreatic Ductal Adenocarcinoma|PTPN11 inhibitor + ERK inhibitor

PD-L1 inhibitor

KRAS G12C|Non Small Cell Lung Cancer|PD-L1 inhibitor

sotorasib + RMC-4630

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + RMC-4630

KRAS G12C|Solid Tumor|sotorasib + RMC-4630

cetuximab + RG6330

KRAS G12C|Colorectal Cancer|cetuximab + RG6330

pembrolizumab

KRAS G12C|Non Small Cell Lung Cancer|pembrolizumab

RMC-4630

KRAS G12C|Non Small Cell Lung Cancer|RMC-4630

JDQ443

KRAS G12C|Non Small Cell Lung Cancer|JDQ443

GEC-255

KRAS G12C|Non Small Cell Lung Cancer|GEC-255

JAB-21822 + JAB-3312

KRAS G12C|Non Small Cell Lung Cancer|JAB-21822 + JAB-3312

MK-1084

KRAS G12C|Non Small Cell Lung Cancer|MK-1084

selumetinib

KRAS G12C|Non Small Cell Lung Cancer|selumetinib

MRTX1257 + IN10018

KRAS G12C|Solid Tumor|MRTX1257 + IN10018

sorafenib + BAY86-9766

KRAS G12C|Hepatocellular Cancer|sorafenib + BAY86-9766

sotorasib + AbGn-107

KRAS G12C|Gastrointestinal Cancer|sotorasib + AbGn-107

sotorasib + VS-6766

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + VS-6766

toripalimab-tpzi

KRAS G12C|Non Small Cell Lung Cancer|toripalimab-tpzi

pembrolizumab + sotorasib

KRAS G12C|Non Small Cell Lung Cancer|pembrolizumab + sotorasib

atezolizumab + sotorasib

KRAS G12C|Non Small Cell Lung Cancer|atezolizumab + sotorasib

nivolumab + rigosertib

KRAS G12C|Non Small Cell Lung Cancer|nivolumab + rigosertib

gemcitabine + paclitaxel

KRAS G12C|Pancreatic Ductal Adenocarcinoma|gemcitabine + paclitaxel

cetuximab + D-1553

KRAS G12C|Colorectal Cancer|cetuximab + D-1553

denosumab

KRAS G12C|Non Small Cell Lung Cancer|denosumab

pembrolizumab + MK-1084

KRAS G12C|Non Small Cell Lung Cancer|pembrolizumab + MK-1084

nivolumab

KRAS G12C|Non Small Cell Lung Cancer|nivolumab

midostaurin + adagrasib

KRAS G12C|Lung Adenocarcinoma|midostaurin + adagrasib

MRTX1257

KRAS G12C|Multiple Myeloma|MRTX1257

erlotinib

KRAS G12C|Non Small Cell Lung Cancer|erlotinib

crizotinib

KRAS G12C|Non Small Cell Lung Cancer|crizotinib

RMC-4550 + RM-029

KRAS G12C|Non Small Cell Lung Cancer|RMC-4550 + RM-029

ramucirumab

KRAS G12C|Non Small Cell Lung Cancer|ramucirumab

adagrasib

KRAS G12C|Non Small Cell Lung Cancer|adagrasib

KRAS G12C|Colorectal Cancer|adagrasib

KRAS G12C|Solid Tumor|adagrasib

KRAS G12C|Pancreatic Cancer|adagrasib

KRAS G12C|Lung Cancer|adagrasib

KRAS G12C|Gastrointestinal Cancer|adagrasib

KRAS G12C|Pancreatic Adenocarcinoma|adagrasib

KRAS G12C|Endometrial Cancer|adagrasib

KRAS G12C|Pancreatic Ductal Adenocarcinoma|adagrasib

KRAS G12C|Ampulla of Vater Carcinoma|adagrasib

KRAS G12C|Lung Adenocarcinoma|adagrasib

KRAS G12C|Ovarian Cancer|adagrasib

KRAS G12C|Biliary Tract Cancer|adagrasib

KRAS G12C|Cholangiocarcinoma|adagrasib

sotorasib + VRx-510

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + VRx-510

KRAS G12C|Pancreatic Cancer|sotorasib + VRx-510

sotorasib + repotrectinib

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + repotrectinib

sotorasib + IN10018

KRAS G12C|Solid Tumor|sotorasib + IN10018

PD-0325901 + BGB-283

KRAS G12C|Solid Tumor|PD-0325901 + BGB-283

regorafenib

KRAS G12C|Colorectal Cancer|regorafenib

sunitinib

KRAS G12C|Colorectal Cancer|sunitinib

sotorasib + adagrasib + VS-6766

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + adagrasib + VS-6766

KRAS G12C|Colorectal Cancer|sotorasib + adagrasib + VS-6766

sotorasib + VS-6766 + VS-6063

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + VS-6766 + VS-6063

selinexor + MRTX1257

KRAS G12C|Non Small Cell Lung Cancer|selinexor + MRTX1257

KRAS G12C|Pancreatic Ductal Adenocarcinoma|selinexor + MRTX1257

afatinib + sotorasib

KRAS G12C|Lung Cancer|afatinib + sotorasib

sotorasib + RMC-4550

KRAS G12C|Lung Cancer|sotorasib + RMC-4550

palbociclib + sotorasib

KRAS G12C|Lung Cancer|palbociclib + sotorasib

sotorasib + selinexor

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + selinexor

KRAS G12C|Pancreatic Ductal Adenocarcinoma|sotorasib + selinexor

trametinib + panitumumab + sotorasib

KRAS G12C|Colorectal Cancer|trametinib + panitumumab + sotorasib

trametinib + sotorasib

KRAS G12C|Colorectal Cancer|trametinib + sotorasib

ASN007

KRAS G12C|Pancreatic Adenocarcinoma|ASN007

sotorasib + DT2216

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + DT2216

KRAS G12C|Colorectal Cancer|sotorasib + DT2216

KRAS G12C|Pancreatic Cancer|sotorasib + DT2216

RG6330 + RLY-1971

KRAS G12C|Non Small Cell Lung Cancer|RG6330 + RLY-1971

APG-1842

KRAS G12C|Non Small Cell Lung Cancer|APG-1842

KRAS G12C|Colorectal Cancer|APG-1842

KRAS G12C|Gastric Cancer|APG-1842

sotorasib + DCC-3116

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + DCC-3116

BMF-219

KRAS G12C|Colorectal Cancer|BMF-219

KRAS G12C|Lung Cancer|BMF-219

TTI-101 oral

KRAS G12C|Lung Adenocarcinoma|TTI-101 oral

TNO155 + JDQ443

KRAS G12C|Solid Tumor|TNO155 + JDQ443

sotorasib + IMM-1-104

KRAS G12C|Pancreatic Cancer|sotorasib + IMM-1-104

trametinib

KRAS G12C|Non Small Cell Lung Cancer|trametinib

KRAS G12C|Pancreatic Cancer|trametinib

panitumumab

KRAS G12C|Colorectal Cancer|panitumumab

adagrasib + ENV-201

KRAS G12C|Lung Cancer|adagrasib + ENV-201

ENV-201

KRAS G12C|Lung Cancer|ENV-201

adagrasib + nanoparticle albumin-bound rapamycin

KRAS G12C|Non Small Cell Lung Cancer|adagrasib + nanoparticle albumin-bound rapamycin

KRAS G12C|Bladder Cancer|adagrasib + nanoparticle albumin-bound rapamycin

sotorasib + nanoparticle albumin-bound rapamycin

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + nanoparticle albumin-bound rapamycin

KRAS G12C|Bladder Cancer|sotorasib + nanoparticle albumin-bound rapamycin

cetuximab

KRAS G12C|Colorectal Cancer|cetuximab

ZG19018 + donafenib

KRAS G12C|Non Small Cell Lung Cancer|ZG19018 + donafenib

ZG19018

KRAS G12C|Non Small Cell Lung Cancer|ZG19018

KRAS G12C|Colorectal Cancer|ZG19018

KRAS G12C|Pancreatic Cancer|ZG19018

tipifarnib

KRAS G12C|Non Small Cell Lung Cancer|tipifarnib

sotorasib + VIC-1911

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + VIC-1911

sotorasib + JSI-1187

KRAS G12C|Colorectal Cancer|sotorasib + JSI-1187

VS-6766

KRAS G12C|Non Small Cell Lung Cancer|VS-6766

YL-17231

KRAS G12C|Solid Tumor|YL-17231

tepotinib

KRAS G12C|Non Small Cell Lung Cancer|tepotinib

RNK07421

KRAS G12C|Non Small Cell Lung Cancer|RNK07421

ABSK071

KRAS G12C|Solid Tumor|ABSK071

sotorasib + OTS514

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + OTS514

OTS514

KRAS G12C|Non Small Cell Lung Cancer|OTS514

BI-2493

KRAS G12C|Solid Tumor|BI-2493

everolimus + ARS-1620

KRAS G12C|Lung Adenocarcinoma|everolimus + ARS-1620

KRAS G12C|Lung Non-Small Cell Squamous Cancer|everolimus + ARS-1620

everolimus + adagrasib

KRAS G12C|Lung Adenocarcinoma|everolimus + adagrasib

KRAS G12C|Lung Non-Small Cell Squamous Cancer|everolimus + adagrasib

everolimus + sotorasib

KRAS G12C|Lung Adenocarcinoma|everolimus + sotorasib

KRAS G12C|Lung Non-Small Cell Squamous Cancer|everolimus + sotorasib

docetaxel

KRAS G12C|Non Small Cell Lung Cancer|docetaxel

sotorasib + KPT-9274

KRAS G12C|Non Small Cell Lung Cancer|sotorasib + KPT-9274

KRAS G12C|Pancreatic Ductal Adenocarcinoma|sotorasib + KPT-9274

bevacizumab

KRAS G12C|Colorectal Cancer|bevacizumab

lorlatinib

KRAS G12C|Non Small Cell Lung Cancer|lorlatinib

sotorasib + midostaurin

KRAS G12C|Lung Adenocarcinoma|sotorasib + midostaurin